@article{oai:twinkle.repo.nii.ac.jp:00017394,
 author = {溝口, 秀昭},
 issue = {4},
 journal = {東京女子医科大学雑誌},
 month = {Apr},
 note = {Recent advances in gene technology have revealed the structure of many hematopoietic growth factors and made them available for clinical use. Hematopoietic growth factors induce the differentiation of hematopoiectic stem cells into mature blood cells, such as red blood cells, granulocytes, macrophages and platelets and control the production of these cells. Erythropoietin is a hematopoietic growth factor which stimulates red cell production and is used clinically for the treatment of renal anemia. Measurement of the serum erythropoietin concentration is useful for the diagnosis of erythrocytosis. Concerning granulopoiesis, 3 kinds of colony-stimulating factors (CSF) have been identified. Among them granulocyte CSF (G-CSF) has been used for neutropenia that occurs after chemotherapy for various cancers and after bone marrow transplantation in Japan. Moreover, it has been confirmed that G-CSF mobilizes stem cells into peripheral blood. Therefore, it is possible to collect peripheral stem cells after administration of G-CSF for use in stem cell transplantation. This method is called peripheral stem cell transplantation (PBSCT). Not only autologous PBSCT but also allogeneic PBSCT has been widely performed. Recently thrombopoietin which stimulates platelet production was discovered and its usefulness in the treatment of thrombocytopenia has been proposed. In the future, these hematopoietic growth factors and other hematopoietic growth factors such as stem cell factor and interleukin 3 may be used to expand stem cells for stem cell transplantation and gene transduction for gene therapy.},
 pages = {203--207},
 title = {造血因子による新しい医療(第25回日本医学会総会プレシンポジウム「先端科学技術と医療」)},
 volume = {69},
 year = {1999}
}